ATNM Actinium Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NYSEAMERICAN: ATNM

Price (delayed)

$9.34

Market cap

$238.01M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.3

Enterprise value

$128.41M

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application ...

Highlights
The quick ratio has decreased by 32% YoY and by 28% from the previous quarter
ATNM's net income is down by 31% year-on-year and by 11% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.actiniumpharma.com
Peers: BMRN FOLD

Key stats

What are the main financial stats of ATNM
Market
Shares outstanding
25.48M
Market cap
$238.01M
Enterprise value
$128.41M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.3
Price to sales (P/S)
223.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
121.94
Earnings
Revenue
$1.05M
EBIT
-$30.38M
EBITDA
-$29.71M
Free cash flow
$11.02M
Per share
EPS
-$1.3
Free cash flow per share
$0.44
Book value per share
$2.83
Revenue per share
$0.04
TBVPS
$4.64
Balance sheet
Total assets
$116.82M
Total liabilities
$45.56M
Debt
$2.6M
Equity
$71.26M
Working capital
$105.07M
Liquidity
Debt to equity
0.04
Current ratio
13.58
Quick ratio
13.44
Net debt/EBITDA
3.69
Margins
EBITDA margin
-2,821%
Gross margin
100%
Net margin
-2,885.1%
Operating margin
-2,930.8%
Efficiency
Return on assets
-30.9%
Return on equity
-41.6%
Return on invested capital
N/A
Return on capital employed
-28%
Return on sales
-2,885.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ATNM stock price

How has the Actinium Pharmaceuticals stock price performed over time
Intraday
1.52%
1 week
0.65%
1 month
0.86%
1 year
84.95%
YTD
-12.3%
QTD
-12.3%

Financial performance

How have Actinium Pharmaceuticals's revenue and profit performed over time
Revenue
$1.05M
Gross profit
$1.05M
Operating income
-$30.86M
Net income
-$30.38M
Gross margin
100%
Net margin
-2,885.1%
Actinium Pharmaceuticals's operating margin has decreased by 41% YoY and by 32% from the previous quarter
The net margin has decreased by 40% YoY and by 31% from the previous quarter
The operating income has declined by 32% year-on-year and by 12% since the previous quarter
ATNM's net income is down by 31% year-on-year and by 11% since the previous quarter

Growth

What is Actinium Pharmaceuticals's growth rate over time

Valuation

What is Actinium Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.3
P/S
223.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
121.94
The EPS has contracted by 7% YoY and by 7% from the previous quarter
The price to book (P/B) is 74% higher than the last 4 quarters average of 1.9 but 15% lower than the 5-year quarterly average of 3.9
The equity has declined by 11% year-on-year and by 9% since the previous quarter
ATNM's price to sales (P/S) is 97% more than its last 4 quarters average of 113.5
ATNM's revenue is down by 15% since the previous quarter and by 6% year-on-year

Efficiency

How efficient is Actinium Pharmaceuticals business performance
The ROS has contracted by 40% YoY and by 31% from the previous quarter
ATNM's return on equity is down by 32% year-on-year and by 15% since the previous quarter
The company's return on assets fell by 3.7% YoY

Dividends

What is ATNM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ATNM.

Financial health

How did Actinium Pharmaceuticals financials performed over time
Actinium Pharmaceuticals's total assets is 156% more than its total liabilities
Actinium Pharmaceuticals's total assets has increased by 38% YoY but it has decreased by 4.1% from the previous quarter
Actinium Pharmaceuticals's current ratio has decreased by 32% YoY and by 28% QoQ
The debt is 96% less than the equity
The company's debt to equity rose by 33% QoQ
The equity has declined by 11% year-on-year and by 9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.